Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats.

Lee KS, Chae SW, Park JH, Park JH, Choi JM, Rhie SJ, Lee HJ.

Xenobiotica. 2013 Mar;43(3):303-10. doi: 10.3109/00498254.2012.731092. Epub 2012 Dec 4.

PMID:
23205514
2.

Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.

Aravagiri M, Marder SR.

Psychopharmacology (Berl). 2002 Feb;159(4):424-31. Epub 2001 Nov 20.

PMID:
11823895
3.

Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.

Vermeulen A, Piotrovsky V, Ludwig EA.

J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):183-206. Epub 2006 Nov 29.

PMID:
17136449
4.
5.

Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.

Mahatthanatrakul W, Sriwiriyajan S, Ridtitid W, Boonleang J, Wongnawa M, Rujimamahasan N, Pipatrattanaseree W.

J Clin Pharm Ther. 2012 Apr;37(2):221-5. doi: 10.1111/j.1365-2710.2011.01271.x. Epub 2011 Apr 26.

PMID:
21518375
6.

In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone.

Titier K, Déridet E, Moore N.

Toxicol Appl Pharmacol. 2002 Apr 15;180(2):145-9.

PMID:
11969382
7.

Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.

De Meulder M, Remmerie BM, de Vries R, Sips LL, Boom S, Hooijschuur EW, van de Merbel NC, Timmerman PM.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):8-16. doi: 10.1016/j.jchromb.2008.04.041. Epub 2008 May 8.

PMID:
18571483
8.

Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand.

Boonleang J, Pipatrattanaseree W, Tanthana C, Mahatthanatrakul W.

Clin Ther. 2010 Sep;32(10):1842-53. doi: 10.1016/j.clinthera.2010.09.013.

PMID:
21194608
9.

Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.

Yoo HD, Cho HY, Lee SN, Yoon H, Lee YB.

J Pharmacokinet Pharmacodyn. 2012 Aug;39(4):329-41. doi: 10.1007/s10928-012-9253-5. Epub 2012 May 24.

PMID:
22623266
10.
11.

Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers.

Lee DY, Lee KU, Kwon JS, Jang IJ, Cho MJ, Shin SG, Woo JI.

Psychopharmacology (Berl). 1999 Jun;144(3):272-8.

PMID:
10435394
12.
13.

Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.

Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S.

Clin Pharmacol Ther. 2005 Jul;78(1):43-51.

PMID:
16003291
14.

Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.

Zhou ZL, Li X, Peng HY, Yu XY, Yang M, Su FL, Wang F, Zhu RH, Deng CY, Lin QX, Wang CY, Li WB, Lin SG, Li HD.

Acta Pharmacol Sin. 2006 Mar;27(3):381-6.

16.

Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.

Kim KA, Park PW, Liu KH, Kim KB, Lee HJ, Shin JG, Park JY.

J Clin Pharmacol. 2008 Jan;48(1):66-72.

PMID:
18094221
17.

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.

Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL.

Int J Neuropsychopharmacol. 2004 Dec;7(4):415-9.

PMID:
15683552
18.

Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.

Citrome L.

Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):873-88. doi: 10.1517/17425255.2012.693160. Epub 2012 May 25. Review.

PMID:
22632481
19.

Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.

Belotto KC, Raposo NR, Ferreira AS, Gattaz WF.

Clin Ther. 2010 Nov;32(12):2106-15. doi: 10.1016/j.clinthera.2010.11.006.

PMID:
21118746
20.

Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.

Duval F, Guillon MS, Mokrani MC, Crocq MA, Garcia Duarte F.

Psychoneuroendocrinology. 2008 Feb;33(2):255-9. Epub 2007 Nov 28.

PMID:
18053652

Supplemental Content

Support Center